Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Integrative Molecular Characterization Of MiT Family Translocation Renal Cell Carcinomas (IMCOR)

NCT05456074 is registered in ClinicalTrials.gov with Institut de cancérologie Strasbourg Europe as lead sponsor.

NCT NCT05456074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05456074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Integrative Molecular Characterization Of MiT Family Translocation Renal Cell Carcinomas (IMCOR)
Lead sponsor
Institut de cancérologie Strasbourg Europe
Phase
Observational
Overall status
Unknown status
Start date
January 25, 2023
Completion date
January 25, 2026
Enrollment
600 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

renal carcinoma